Home › Precursor T-Cell Lymphoblastic Leukemia-Lymphoma › NCT00501826

Combination Chemotherapy and Nelarabine in Treating Patients With T-cell Acute Lymphoblastic Leukemia or Lymphoblastic Lymphoma

Phase II Study of Hyper-CVAD Plus Nelarabine in Previously Untreated T-ALL and Lymphoblastic Lymphoma

Who can join

All ages · All sexes

Inclusion Criteria:

* Previously untreated T cell ALL including T cell lymphoblastic lymphoma; failure to one induction course of chemotherapy are eligible; patients in CR after =\< 2 courses are also eligible
* Eastern Cooperative Oncology Group (ECOG) performance status less than or equal to 3
* Serum bilirubin less than or equal to 2.0 mg/dL unless considered due to involvement by tumor when an upper limit of 5.0 mg/dL is acceptable
* Serum glutamic oxaloacetic transaminase (SGOT) or serum glutamate pyruvate transaminase (SGPT) less than or equal to 4 x upper limit of normal (ULN)
* Serum creatinine less than or equal to 2.0 mg/dL unless considered due to involvement by tumor when an upper limit of 2.5 mg/dL is acceptable

Exclusion Criteria:

* Pregnant or nursing women

About the study

This phase II trial studies the side effects and how well combination chemotherapy and nelarabine work in treating patients with T-cell acute lymphoblastic leukemia or lymphoblastic lymphoma. Drugs used in chemotherapy, such as cyclophosphamide, vincristine, doxorubicin, dexamethasone, methotrexate, cytarabine, mercaptopurine, prednisone, pegaspargase, nelarabine, and venetoclax work in different ways to stop the growth of cancer cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading.

What is being tested

• Cyclophosphamide (drug)
• Cytarabine (drug)
• Dexamethasone (drug)
• Doxorubicin Hydrochloride (drug)
• Mercaptopurine (drug)
• Methotrexate (drug)

Sponsor: M.D. Anderson Cancer Center · Participants: 160 · Started: Jul 11, 2007

Contact the study team

• Farhad Ravandi-Kashani, MD · Phone: 713-745-0394

Official record on ClinicalTrials.gov — NCT00501826

Locations in the U.S.

Conditions

• Precursor T-Cell Lymphoblastic Leukemia-Lymphoma

From ClinicalTrials.gov, data retrieved Sep 30, 2026. Each study sets its own eligibility; the study team decides who can join.